Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
07:00am, Tuesday, 06'th Dec 2022
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel rout
Tiziana Life Sciences publishes peer-reviewed research, showing intranasal administered drug for autoimmune diseases is safe in humans
11:41am, Wednesday, 23'rd Nov 2022
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has published a scientific article in the peer-reviewed journal Frontiers in Immunology, showing a favorable safety profile for intranasally administere
Is Your 60/40 Portfolio Failing? GraniteShares Offers Help
07:00am, Friday, 04'th Nov 2022
High conviction is what it takes to build and launch the best ETFs at GraniteShares. And that's a solution for disappointing 60/40 portfolios.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the start of enrollment of the first patient cohort in its intermediate-size patient population expanded access program to evaluate foralumab in n
Tiziana Life Sciences plans to submit IND for phase 1 trial of intranasal foralumab in Alzheimer's disease patients by Q3 2023
07:50am, Wednesday, 12'th Oct 2022
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that it plans to submit an Investigational New Drug Application (IND) for a phase 1 trial of intranasal foralumab in Alzheimer's disease patients.
Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy
10:47am, Wednesday, 28'th Sep 2022
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has presented posters on intranasal foralumab at the Preserving the Brain scientific conference, a scientific forum and exhibit on neurodegenerative diseases as
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported further positive results from a patient with non-active secondary progressive multiple sclerosis (SPMS) being treated with the company's intranasal
Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALS
08:13am, Thursday, 15'th Sep 2022
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Brigham and Women's Hospital (BWH) will receive a grant to explore the use of intranasal anti-CD3 monoclonal antibody (mAb) in the nervous sy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the presentation of a study entitled, 'Treatment of Alzheimer's disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb' at th
Tiziana Life Sciences Ltd said it has appointed Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately. The company noted that Dr Davis will report t
Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient
12:11pm, Wednesday, 08'th Jun 2022
Tiziana Life Sciences (NASDAQ: TLSA) reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program.
Tiziana Life Sciences reports positive results from second patient in multiple sclerosis study of foralumab
09:32am, Wednesday, 08'th Jun 2022
Tiziana Life Sciences PLC (NASDAQ:TLSA) said a second patient with Secondary Progressive Multiple Sclerosis (SPMS) in an ongoing study has shown clinical improvements following three months of treatm
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
03:43pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of immuno
Tiziana Life Sciences PLC (NASDAQ:TLSA) said the US Food and Drug Administration (FDA) has given permission for the enrollment of additional Secondary Progressive Multiple Sclerosis (SPMS) patients fo
